RxDoctor Payments DataLook up a doctor →

Melissa Desueza

Family · Paterson, NJNPI 1235634189

Payments from drug & device makers

$9,345in general payments, 2019–2025

Across 474 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$972
  • Boehringer Ingelheim$941
  • Ironwood Pharmaceuticals, Inc$936
  • AbbVie$925
  • GSK$467
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$9,345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,345 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$18,285
Medicare patients
48
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl163$163,192
LinzessLinaclotide146$145,807
OzempicSemaglutide100$100,687
RybelsusSemaglutide59$89,969
JardianceEmpagliflozin73$87,038
ProliaDenosumab40$68,420
FarxigaDapagliflozin Propanediol69$66,176
JanuviaSitagliptin Phosphate65$62,266
TradjentaLinagliptin48$38,926
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$37,809
VascepaIcosapent Ethyl52$34,989
MounjaroTirzepatide34$34,069
EliquisApixaban30$33,755
Janumet XrSitagliptin Phos/Metformin Hcl32$28,218
TrulicityDulaglutide27$27,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Janumet Xr, Belsomra$223$258,677271 claims
Novo NordiskOzempic, Rybelsus$1,125$190,657159 claims
AbbVieLinzess$925$145,807146 claims
Boehringer IngelheimJardiance, Tradjenta$941$125,964121 claims
AmgenProlia$972$68,42040 claims
AstraZenecaFarxiga$263$66,17669 claims
Lilly USA, LLCMounjaro, Trulicity$284$61,79461 claims
GSKTrelegy Ellipta$467$37,80953 claims
PfizerEliquis$216$33,75530 claims
NovartisEntresto$99$24,59021 claims
Astellas Pharma US IncMyrbetriq$28$9,85314 claims
BayerKerendia$336$8,01813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.

Other family in Paterson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →